CKChul Joo Kang

Chul Joo Kang

*This is an algorithmically generated author record based on publicly available information.

Chul Joo Kang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Nathan O. Stitziel

    Washington University School of Medicine

    2 shared publications
  • Alessia Di Costanzo

    Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy

    1 shared publication
  • Anna Montali

    Departments of Translational and Precision Medicine (L.D’E., A.D.C., I.M., S.B., M.M., G.P., A.M., M.A.), Sapienza University of Rome, Italy

    1 shared publication
  • Antonio Nicolucci

    CORESEARCH Srl - Center for Outcomes Research and Clinical Epidemiology - Co. Ltd, Pescara, Italy (G.L., A.N.).

    1 shared publication
  • Arturo Alisio

    Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, USA

    1 shared publication
  • Babak Razani

    Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA

    1 shared publication

Latest Publications

  • Open Access

    Variant Set Distillation

    by Ryan Christ, Chul Joo Kang, Louis J.M. Aslett, Daniel Lam, Maria Faelth Savitski, Nathan Stitziel, David Steinsaltz, Ira Hall

    Allelic heterogeneity – the presence of multiple causal variants at a given locus – has been widely observed across human traits. Combining the association signals across these distinct causal variants at a given locus presents an opportunity for empowering gene discovery. This opportunity is growing with the increasing population diversity and sequencing depth of emerging genomic datasets. However, the rapidly increasing number of null (non-causal) variants within these datasets makes leveraging allelic heterogeneity increasingly difficult for existing testing approaches. We recently-proposed a general theoretical framework for sparse signal problems, Stable Distillation (SD). Here we present a SD-based method vsdistill , which overcomes several major shortcomings in the simple SD procedures we initially proposed and introduces many innovations aimed at maximizing power in the context of genomics. We show via simulations that vsdistill provides a significant power boost over the popular STAAR method. vsdistill is available in our new R package gdistill , with core routines implemented in C. We also show our method scales readily to large datasets by performing an association analysis with height in the UK Biobank.

  • ANGPTL3 Deficiency and Risk of Hepatic Steatosis

    by Laura D’eRasmo, Michele Di Martino, Thomas Neufeld, Tyler J. Fraum, Chul Joo Kang, Kendall H. Burks, Alessia Di Costanzo, Ilenia Minicocci, Simone Bini, Marianna Maranghi, et al.

    BACKGROUND: ANGPTL3 (angiopoietin-like 3) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3. METHODS: We recruited participants with ANGPTL3 deficiency related to ANGPTL3 loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St. Louis, MO. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction were performed to measure hepatic fat fraction and the distribution of extrahepatic fat. To estimate the causal relationship between ANGPTL3 and hepatic fat, we generated a genetic instrument of plasma ANGPTL3 levels as a surrogate for hepatic protein synthesis and performed Mendelian randomization analyses with hepatic fat in the UK Biobank study. RESULTS: We recruited participants with complete (n=6) or partial (n=32) ANGPTL3 deficiency related to ANGPTL3 LoF mutations, as well as WT participants (n=92) without LoF mutations. Participants with ANGPTL3 deficiency exhibited significantly lower total cholesterol (complete deficiency, 78.5 mg/dL; partial deficiency, 172 mg/dL; WT, 188 mg/dL; P P 0.05 for both deficiency groups compared with WT) or severity of hepatic steatosis as assessed by magnetic resonance imaging. In addition, ANGPTL3 deficiency did not alter the distribution of extrahepatic fat. Results from Mendelian randomization analyses in 36 703 participants from the UK Biobank demonstrated that genetically determined ANGPTL3 plasma protein levels were causally associated with low-density lipoprotein cholesterol ( P =1.7×10 -17 ) and triglycerides ( P =3.2×10 -18 ) but not with hepatic fat ( P =0.22). CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3 , as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.


  • SVEP1 is a human coronary artery disease locus that promotes atherosclerosis

    by In-Hyuk Jung, Jared S. Elenbaas, Arturo Alisio, Katherine Santana, Erica P. Young, Chul Joo Kang, Puja Kachroo, Kory J. Lavine, Babak Razani, Robert P. Mecham, et al.

    A low-frequency variant of sushi, von Willebrand factor type A, EGF, and pentraxin domain-containing protein 1 (SVEP1), an extracellular matrix protein, is associated with risk of coronary disease in humans independent of plasma lipids. Despite a robust statistical association, if and how SVEP1 might contribute to atherosclerosis remained unclear. Here, using Mendelian randomization and complementary mouse models, we provide evidence that SVEP1 promotes atherosclerosis in humans and mice and is expressed by vascular smooth muscle cells (VSMCs) within the atherosclerotic plaque. VSMCs also interact with SVEP1, causing proliferation and dysregulation of key differentiation pathways, including integrin and Notch signaling. Fibroblast growth factor receptor transcription increases in VSMCs interacting with SVEP1 and is further increased by the coronary disease–associated SVEP1 variant p.D2702G. These effects ultimately drive inflammation and promote atherosclerosis. Together, our results suggest that VSMC-derived SVEP1 is a proatherogenic factor and support the concept that pharmacological inhibition of SVEP1 should protect against atherosclerosis in humans.